Clinical Trials Directory

Trials / Terminated

TerminatedNCT05019105

Phase 1 ALKS 1140 in Healthy Adults

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Escalating Doses of ALKS 1140 With a Pilot Evaluation of Food Effect in Healthy Adult Subjects

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Alkermes, Inc. · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

To evaluate the safety and tolerability of ALKS 1140 in healthy adult subjects

Conditions

Interventions

TypeNameDescription
DRUGPlaceboOral matching placebo
DRUGALKS 1140Active oral dose of ALKS 1140

Timeline

Start date
2021-10-13
Primary completion
2022-08-23
Completion
2022-08-23
First posted
2021-08-24
Last updated
2022-09-02

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT05019105. Inclusion in this directory is not an endorsement.

Phase 1 ALKS 1140 in Healthy Adults (NCT05019105) · Clinical Trials Directory